



EUROPEAN CANCER PATIENT COALITION

“Nothing about us without us!” ECPC

ECPC is the unified voice of cancer patients across Europe

The European Cancer Patient Coalition (ECPC) works for a Europe of equality, where all European cancer patients have timely and affordable access to the best treatment and care available, throughout their life. ECPC believes that cancer patients are the most important partners in the fight against cancer and against all the cancer-related issues affecting our society. Policy makers, researchers, doctors and industry should recognise cancer patients as co-creators of their own health.

The European cancer patient Coalition participates in several European Union's Research and Innovation framework programmes, among others: this includes **IMI 1** projects, the **Seventh Framework Programme (FP7)** and **IMI 2** projects under the current **Horizon 2020 (H2020)**.

Join us for our AGM 2017


JOIN NOW



ERNs Launch in Vilnius

March 9th-10th 2017 marked an important milestone in the history of EU cooperation in the field of healthcare. The **European Reference Networks Conference (ERN)** kick-off meeting was held in Vilnius, the home country of Commissioner Vytenis Andriukaitis, organized by the **European Commission** under the auspices of the **Maltese Presidency** of the Council of the EU and hosted by the **Ministry of Health** of Lithuania.

The event witnessed the formally launching of the 24 European Reference Networks (ERNs) dealing with rare and low prevalence complex medical conditions bring together 25 EU Member States plus Norway from more than 300 hospitals and 1000 healthcare units of expertise covering all major disease groups.



ECPC is honoured to be one of the patient organisations representing the needs, rights and hopes of rare cancer patients as a European Patient Advisory Group Representative under the **ERN for solid and rare cancers coordinated (EURACAN)** by the **Centre Leon Bernard** in collaboration with **EURORDIS**, and a co-chairing the Taskforce under Communication and Dissemination.

The EURACAN ERN gathers all rare adult solid cancers which are grouped in 10 domains corresponding to the **RARECARE and RARECARENet** classification in addition to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10).



[Contact us here!](#)



JOIN NOW: Working Group on Rare Cancers



The **Joint Action on Rare Cancers** is aimed to integrate and maximize efforts of the European Commission and EU Member States to advance quality of care and research on rare cancers. The public health challenge posed by rare cancers combines both the typical problems of rare diseases and cancers where the need of timely diagnosis and access to quality treatment is vital. Accordingly, **JARC** is shaping its efforts around the **European Reference Networks (ERNs)**.

The **Joint Action on Rare Cancers** and the **European Reference Networks** are crucial game changers for rare cancer patients in Europe bringing together scarce knowledge and fragmented resources to maximise synergies and results.

The European Cancer Patient Coalition counts on the expertise and collaboration of rare cancer patient organisations all over Europe to continuously represent the rare cancer patient community. **ECPC invites patient experts, members and non-member organisations with are interested in rare cancers to join our Working group on Rare Cancers (WGRC).**

The **Working Group on Rare Cancers (WGRC) works in parallel with the JARC**, in order to guarantee that a large number of rare cancer patient organisations, representing different European countries and rare cancer types, will be able to contribute to the activities of the JARC. **JOIN NOW!**

IMI2 Big Data for Better Outcomes (BD4BO) Coordination and Support Action launched

On February 2017, a public-private consortium was launched to facilitate the transition towards **outcomes-focused healthcare systems** across Europe. A wealth of emerging data from evolving data sources provides an opportunity for healthcare systems to measure **outcomes that matter to patients, allowing resources to be focused on highly effective treatments.**



Contact us [here!](#)



BD4BO-DO>IT is a two-year project funded by the European Commission's **Innovative Medicines Initiative (IMI) 2** programme launched to facilitate the transition towards outcomes-focused healthcare systems across Europe.

Over the next two years, the Big Data for Better Outcomes, Policy Innovation, and Healthcare Systems Transformation (**BD4BO-DO>IT**) consortium will coordinate the **IMI 2 Big Data for Better Outcomes (BD4BO) programme**, identifying and addressing opportunities for data-driven healthcare system transformation based on input from healthcare systems stakeholders and on knowledge, data and tools developed in the BD4BO disease specific projects: **Alzheimer's Disease, hematologic malignancies, cardiovascular diseases and prostate cancer.**

[Press Release: New public-private partnership launched](#)

PREFER Editorial: Giving patients' preferences a voice in drug development

prefer.
PATIENT PREFERENCES

PREFER is a five-year project funded by the European Commission's **Innovative Medicines Initiative (IMI) 2** programme to evaluate different ways of assessing clinical patient preferences.

The project will establish recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products.

The European Cancer Patient Coalition (ECPC) is one of the four patient organisations in the Patient Advisory Group of the project. The role of ECPC is to lead the Patient Advisory Group and to ensure that the methodologies identified are consistent with the specific views, experiences and preferences of patients.

[Read article in Patient](#)



[Contact us here!](#)

